Impact of blood electrolyte parameters on the incidence of paroxysmal atrial fibrillation in patients with chronic kidney disease with and without albuminuria

Aim. To evaluate the impact of blood electrolytes, parathyroid hormone, and vitamin D on the incidence of paroxysmal atrial fibrillation (AF) in patients with chronic kidney disease (CKD) with and without albuminuria.

Material and methods. A total of 76 patients with paroxysmal AF were examined and divided into three groups. The first group included 23 patients with AF but no CKD, while the second group — 28 patients with AF and CKD, and the third group — 25 patients with AF and CKD and albuminuria. The diagnosis in all cases was confirmed by anamnestic, clinical, electrocardiographic, and laboratory data. Prediction of the clinical course of AF was performed using multiple linear regression. There is a following multiple regression equation: Y_x = a₀ + b₁´X₁ + b₂´X₂ + b₃´X₃, where Y_x is the dependent variable, a₀ is the intercept, b_1,2,3 are the regression coefficients, and X_1,2,3 are the independent variables.

Results. A close relationship has been established between the incidence of atrial fibrillation in stage C3a CKD and blood electrolyte levels, parathyroid hormone, and vitamin D. A mathematical model for predicting the incidence of atrial fibrillation in patients with stage C3a CKD was developed based on blood electrolytes, parathyroid hormone, and vitamin D levels.

Conclusion. Blood electrolyte levels, parathyroid hormone, and vitamin D levels can be used to construct a predictive model for estimating the incidence of paroxysmal atrial fibrillation.

1. Druzhilov MA, Kuznetsova TYu, Druzhilova OYu, et al. At­rial fibril­la­tion and chronic kidney disease: main clinical cha­rac­teristics of pa­tients in selected subjects of the Rus­sian Fede­ration. Car­dio­vas­cular Therapy and Prevention. 2023;22(4):3544. (In Russ.) doi:10.15829/1728-8800-2023-3544.

2. Turakhia MP, Blankestijn PJ, Carrero J, et al. Chronic kidney di­sease and arrhythmias: conclusions from a kidney disease: im­pro­ving global outcomes (kdigo) controversies conference. Neph­ro­logy (Saint-­Petersburg). 2019;23(2):18-40. (In Russ.) doi:10.24884/1561-6274-2019-23-2-18-40.

3. Kobalava ZD, Lazarev PV, Vatsik MV. New aspects of anti­coa­gulant therapy in atrial fibrillation in patients with renal dysfunc­tion. Russian Journal of Cardiology. 2020;25(11):4175. (In Russ.) doi:10.15829/29/1560-4071-2020-4175. EDN: BPGOJB.

4. Novikova TN. Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function. Kardiologiia. 2021; 61(10):81-8. (In Russ.) doi:10.18087/cardio.2021.10.n1767.

5. Ravera M, Bussalino E, Fusaro M, et al. Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspective. J Nephrol. 2020; 33(3):483-95. doi:10.1007/s40620-020-00720-5.

6. Chashkina MI, Kozlovskaya NL, Andreev DA, et al. Prevalence of Ad­vanced Chronic Kidney Disease in Patients with Nonvalvular At­rial Fibrillation Hospitalized in Cardiology Departments. Kar­dio­logiia. 2020;60(2):41-6. (In Russ.) doi:10.18087/cardio.2020.2.n823.

7. Zagidullin NSh, Davtyan PA. Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease. Rus­sian Journal of Cardiology. 2021;26(3S):4676. (In Russ.) doi:10.15829/1560-4071-2021-4676.

8. Sarnak M, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-­Art Review. J Am Coll Cardiol. 2019;74(14):1823-1838. doi:10.1016/j.jacc.2019.08.1017.

9. Arnson Y, Hoshen M, Berliner-­Sendrey A, et al. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Cardiology. 2020;145(3):178-86. doi:10.1159/000504877.

10. Liampas E, Kartas A, Samaras A, et al. Renal function and mor­tality in patients with atrial fibrillation. J Cardiovasc Med. 2022; 23(7):430-8. doi:10.2459/JCM.0000000000001308.

11. Ortiz А, Wanner С, Gansevoort R, et al. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Eur J Prev Cardiol. 2022;29(17):2211-5. doi:10.1093/eurjpc/zwac186.

12. Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Kar­diologiia. 2022;62(4):12-9. (In Russ.) doi:10.18087/cardio.2022.4.n1997.

13. Rakhmatullov RF, Shatalina LK, Rakhmatullov FK, et al. The effect of warfarin, metoprolol and their combination on electro­cardiographic and electrophysiological parameters of the heart in patients with atrial fibrillation and chronic kidney disease. Modern problems of science and education. 2024;3. (In Russ.) doi:10.17513/spno.33422.

14. Zaitseva AK, Karpushev AV, Zhorov BS, et al. Biophysical me­cha­nisms of sodium channelopathies in myocardium: long qt syn­dro­me and brugada syndrome. I. M. Sechenov Rus­sian Journal of Physio­lo­gy. 2019;105(1):3-23. (In Russ.) doi:10.1134/S0869813919010102.

15. Gusev K, Khudiakov A, Zaytseva A, et al. Impact of the DSP-H1684R genetic variant on ion channels activity in ipsc-derived cardiomyocytes. Cell Physiol Biochem. 2020;54(4):696-706. doi:10.33594/000000249.

16. Khudiakov A, Zaytseva A, Perepelina K, et al. Sodium current abnormalities and deregulation of Wnt/β-catenin signaling in iPSC-derived cardiomyocytes generated from patient with arrhythmogenic cardiomyopathy harboring compound genetic variants in plakophilin 2 gene. Biochim Biophys Acta Mol Basis Dis. 2020;1866(11):165915. doi:10.1016/j.bbadis.2020.165915.

17. Zaytseva A, Karpushev А, Kiselev А, et al. Characterization of a novel SCN5A genetic variant A1294G associated with mixed clinical phenotype. Biochem Biophys Res Commun. 2019;516(3):777-83. doi:10.1016/j.bbrc.2019.06.080.

18. Zaytseva А, Boitsov A, Kostareva A, et al. Possible Interactions of Extracellular Loop IVP2-S6 With Voltage-­Sensing Domain III in Cardiac Sodium Channel. Front Pharmacol. 2021;12:742508. doi:10.3389/fphar.2021.742508.

19. Korkosh V, Zaytseva A, Kostareva А, et al. Intersegment Con­tacts of Potentially Damaging Variants of Cardiac Sodium Chan­nel. Front. Pharmacol. 2021;12:756415. doi:10.3389/fphar.2021.756415.